H.C. Wainwright analyst Robert Burns raised the firm’s price target on Zymeworks to $10 from $8 and keeps a Neutral rating on the shares following the Q4 report. The analyst considers the zanidatamab data very positive when benchmarked against KEYNOTE-811.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZYME: